Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Self-complementary adeno-associated virus (scAAV) vectors can significantly minimize the vector load required to achieve sustained transgene expression. In this study, transcriptional regulatory elements were systematically screened to produce constitutive and liver-specific scAAV factor IX (FIX) expression cassettes. In addition, optimization of GC content, cis- regulatory elements, and codon usage in the human FIX (hFIX) transgene increased expression 4-20-fold. A vector was developed that was capable of expressing high FIX levels in comparison with the single-stranded (ss) AAV vector used in a recent clinical trial. The ssAAV and scAAV vectors display different transgene expression and genome stability patterns in the liver, as determined by immunohistochemical staining, in situ messenger RNA (mRNA) hybridization and vector genome quantitation. The ssAAV2 vector promoted strong FIX expression in only a subset of hepatocytes. The scAAV2-hFIX vector showed widespread ( approximately 80% of hepatocytes), moderate FIX expression levels similar to normal livers with correction of coagulation function in FIX-deficient mice. The ability of low dose scAAV-FIX vectors to achieve near-physiological expression may circumvent inflammatory responses in the liver. In addition to providing an improved scAAV vector for potential application in future hemophilia B clinical trials and liver-directed gene delivery, these studies underscore the need for rigorous analysis and optimization of vector genome cassettes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The bGHpolyA turned out to be the strongest for the FIX gene expression, outperforming other polyA sequences such as the synthetic polyA, mouse β-globin pA, rabbit β-globin pA, and H4-based pA [143].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [143]
In the citing paper
“Especially, the strong MVM intron-1 of the viral capsid protein (VP-1) of only 67-to-97 bp can increase the transcript expression by 10× [143].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [143]
In the citing paper
“Strikingly, introducing the Minute virus of mice (MVM) intron between promoter and transgene has been reported to increase 80-fold of transgene expression in liver cells compared to intron-null AAV [24].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [24]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
Self-citationMcCarty, D., Monahan, P., & Samulski, R. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301514 · Cited by 735
Self-citationFisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547
McCarty, D. M., Fu, H., Monahan, P. E., Toulson, C. E., Naik, P., & Samulski, R. J. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302134 · Cited by 547
Self-citationCodon usage limitation in the expression of HIV-1 envelope glycoprotein
Haas, J., Park, E.-C., & Seed, B. (1996) · Current Biology · doi:10.1016/s0960-9822(02)00482-7 · Cited by 532
High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells
Kudla, G., Lipinski, L., Caffin, F., Helwak, A., & Zylicz, M. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040180 · Cited by 476
Nathwani, A. C., Gray, J. T., Ng, C. Y. C., Zhou, J., Spence, Y., Waddington, S. N., Tuddenham, E. G. D., Kemball-Cook, G., McIntosh, J., Boon-Spijker, M., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4035 · Cited by 421
Cited by
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Self-citationEffect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Self-citationEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Self-complementary AAV vectors; advances and applications
McCarty, D. M. (2008) · Molecular Therapy · doi:10.1038/mt.2008.171 · Cited by 515
Gray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420
“Thus, a major challenge in effectively using scAAV vectors has been to combine minimal promoter, intron, and polyadenylation [poly(A)] elements in order to maximize the remaining space for the transgene-coding sequence (Wu et al., 2008).”
BackgroundSelf-citationAAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
“A number of intronic sequences of varying length have been described and used in combination with different promoters (hybrid beta-actin/beta-globin, 238 hybrid adenovirus/immunoglobin, 239 hybrid beta-globin/ Ig heavy chain or minute virus of mice (MVM) 240 ).”
Self-citationMicrovesicle-associated AAV Vector as a Novel Gene Delivery System
Maguire, C. A., Balaj, L., Sivaraman, S., Crommentuijn, M. H., Ericsson, M., Mincheva-Nilsson, L., Baranov, V., Gianni, D., Tannous, B. A., Sena-Esteves, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.303 · Cited by 283
Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246
Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy
Balakrishnan, B., & Jayandharan, G. (2014) · Current Gene Therapy · doi:10.2174/1566523214666140302193709 · Cited by 225
“4Kb which limits its use for delivering large genes [185, 186].”
Adeno-Associated Virus Vectorology, Manufacturing, and Clinical Applications
Grieger, J. C., & Samulski, R. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-386509-0.00012-0 · Cited by 199
“…Wu et al. systematically screened transcriptional regulatory elements to produce constitutive and liver-specific scAAV FIX expression cassettes that increased expression 4–20-fold when compared to a single-stranded rAAV vector that was used in a recent clinical trial (Wu et al., 2008).”
BackgroundMethodInfluentialSelf-citationDavis, J. R., Wang, X., Witte, I. P., Huang, T. P., Levy, J. M., Raguram, A., Banskota, S., Seidah, N. G., Musunuru, K., & Liu, D. R. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00911-4 · Cited by 192
Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
Self-citationParkinson's Disease Gene Therapy: Success by Design Meets Failure by Efficacy
Bartus, R. T., Weinberg, M. S., & Samulski, R. J. (2014) · Molecular Therapy · doi:10.1038/mt.2013.281 · Cited by 164
Self-citationEnhancement of Adeno-Associated Virus Infection by Mobilizing Capsids into and Out of the Nucleolus
Johnson, J. S., & Samulski, R. J. (2009) · Journal of Virology · doi:10.1128/jvi.02309-08 · Cited by 162
“This may help explain why some investigators observe a threshold effect with AAV vectors following in vivo administration (44, 66).”
BackgroundSelf-citationNext-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147
The University of North Carolina at Chapel Hill University Libraries (2015) · The University of North Carolina at Chapel Hill University Libraries · doi:10.17615/2x9m-k248 · Cited by 145
Young, S., & Neher, E. (2009) · Neuron · doi:10.1016/j.neuron.2009.07.028 · Cited by 144
“We call this the pUNISHER plasmid. pUNISHER combines previous optimizations of the transcriptional (Hioki et al., 2007), translational (Brun et al., 2003), and posttranscriptional signals (Brun et al., 2003; Wu et al., 2008; Xu et al., 2002) for transgene expression into one vector.”
Adeno-Associated Virus Biology
Weitzman, M. D., & Linden, R. M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_1 · Cited by 132
Monahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125
Self-citationShao, W., Earley, L. F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M. L., Ting, J., Samulski, R. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120474 · Cited by 119
Self-citationMethods for Gene Transfer to the Central Nervous System
Kantor, B., Bailey, R. M., Wimberly, K., Kalburgi, S. N., & Gray, S. J. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00003-2 · Cited by 109
“A comparison of different polyA signals, including the mouse α-globin polyA, the bovine growth hormone polyA, and a synthetic polyA showed that by utilizing different polyA sequences expression could be modulated over a 7-fold range (Wu et al., 2008).”
BackgroundInfluentialMonahan, P. E., Sun, J., Gui, T., Hu, G., Hannah, W. B., Wichlan, D. G., Wu, Z., Grieger, J. C., Li, C., Suwanmanee, T., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.106 · Cited by 108
“We previously reported our effort to identify compact yet strong regulatory elements to direct factor IX gene expression in the liver from self-complementing AAV vectors.(6) A similar effort reported by Nathwani and colleagues led to the development of the scAAV2/8-LP1-hFIXco vector used in the SJCRH/UCL human clinica…”
MethodSelf-citationCRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice
Stone, D., Long, K. R., Loprieno, M. A., Feelixge, H. S. D. S., Kenkel, E. J., Liley, R. M., Rapp, S., Roychoudhury, P., Nguyen, T., Stensland, L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.014 · Cited by 101
“To enhance SaCas9 expression we fused the short EF1a promoter to a minute virus of mice intron, which can increase promoter expression levels from AAV vectors in vivo.(40,41) This hybrid EFM promoter is only 325 bp in length, which enables incorporation of two sgRNA expression cassettes in the same AAV-SaCas9 vector.”
MethodAAV vector development, back to the future
Suárez-Amarán, L., Song, L., Tretiakova, A. P., Mikhail, S., & Samulski, R. J. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.064 · Cited by 101
Self-citationBuck, T., & Wijnholds, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124197 · Cited by 92
“Especially, the strong MVM intron-1 of the viral capsid protein (VP-1) of only 67-to-97 bp can increase the transcript expression by 10x [143].”
BackgroundInfluentialMonahan, P. E., Négrier, C., Tarantino, M., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85
“In some experimental models, FIX encoded by scAAV vectors is expressed earlier and at a higher level than when it is encoded by conventional ssAAV vectors [98,103,104].”
BackgroundSelf-citationLiver induced transgene tolerance with AAV vectors
Keeler, G. D., Markusic, D. M., & Hoffman, B. E. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2017.12.002 · Cited by 81
“In some instances, the increased expression levels have been dramatic with a 37-fold increase seen in FVIII expression levels [124], 21-fold increase seen with hFIX [125] and a ~50-fold increase in human ornithine transcarbamylase (hOTC) expression levels in hepatocytes [126].”
BackgroundChuah, M. K., Petrus, I., De Bleser, P., Le Guiner, C., Gernoux, G., Adjali, O., Nair, N., Willems, J., Evens, H., Rincon, M. Y., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.114 · Cited by 80
Cellular immune response to cryptic epitopes during therapeutic gene transfer
Li, C., Goudy, K., Hirsch, M., Asokan, A., Fan, Y., Alexander, J., Sun, J., Monahan, P., Seiber, D., Sidney, J., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902269106 · Cited by 79
“In other work, we have generated a codon-optimized F9 construct (F9-opt), which induces higher F9 production in mice after AAV delivery compared with the wild-type F9 cDNA (15).”
BackgroundSelf-citationSuccessful treatment of canine hemophilia by continuous expression of canine FVIIa
Margaritis, P., Roy, E., Aljamali, M. N., Downey, H. D., Giger, U., Zhou, S., Merricks, E., Dillow, A., Ezban, M., Nichols, T. C., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168377 · Cited by 77
Enhancing transduction of the liver by adeno-associated viral vectors
Nathwani, A. C., Cochrane, M., McIntosh, J., Ng, C. Y. C., Zhou, J., Gray, J. T., & Davidoff, A. M. (2009) · Gene Therapy · doi:10.1038/gt.2008.137 · Cited by 77
Gene therapy for liver diseases — progress and challenges
Zabaleta, N., Unzu, C., Weber, N. D., & González‐Aseguinolaza, G. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00729-0 · Cited by 80
Nichols, T. C., Dillow, A. M., Franck, H. W. G., Merricks, E. P., Raymer, R. A., Bellinger, D. A., Arruda, V. R., & High, K. A. (2009) · ILAR Journal · doi:10.1093/ilar.50.2.144 · Cited by 73
“Future liver-based studies in humans may require optimization of the expression cassette (Wu et al. 2008) or immunomodulation to achieve long-term expression.”
BackgroundRonzitti, G., Bortolussi, G., van Dijk, R., Collaud, F., Charles, S., Leborgne, C., Vidal, P., Martin, S., Gjata, B., Sola, M. S., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.49 · Cited by 69
Sabatino, D. E., Nichols, T. C., Merricks, E., Bellinger, D. A., Herzog, R. W., & Monahan, P. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-394596-9.00006-8 · Cited by 66
“expression occured in a homogeneous FIX expression across the liver parenchyma.(250) scAAV vectors also demonstrated this physiologic FIX expression pattern, whereas expression from the conventional single-strand AAV2–FIX vector occurred in an intense pattern in only a small subset of cells, in which expression was in…”
BackgroundSelf-citationSun, J., Hakobyan, N., Valentino, L. A., Feldman, B. L., Samulski, R. J., & Monahan, P. E. (2008) · Blood · doi:10.1182/blood-2008-01-131417 · Cited by 68
Self-citationWu, T., Töpfer, K., Lin, S.-W., Li, H., Bian, A., Zhou, X. Y., High, K. A., & Ertl, H. C. (2012) · Molecular Therapy · doi:10.1038/mt.2011.280 · Cited by 66
Adeno-Associated Virus Vectors: Principles, Practices, and Prospects in Gene Therapy
Zwi‐Dantsis, L., Mohamed, S., Massaro, G., & Moeendarbary, E. (2025) · Viruses · doi:10.3390/v17020239 · Cited by 76
“Additionally, this change leads to more stable transgene expression, leveraging the intrinsic advantages of the double-stranded format while maintaining similar elements to those in the single-stranded rAAV cassette [27,28].”
Li, C., Xiao, P., Gray, S. J., Weinberg, M. S., & Samulski, R. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1109522108 · Cited by 66
“In our prior study, utilization of an optimized coagulation factor 9 (F9) induced fivefold higher transgene expression than a wild-type F9 construct with AAV delivery (9).”
BackgroundInfluentialSelf-citationAdvancements in the design and scalable production of viral gene transfer vectors
Sharon, D., & Kamen, A. (2018) · Biotechnology and Bioengineering · doi:10.1002/bit.26461 · Cited by 59
“…in a variety of tissues provide strong in vivo evidence that although ssAAV vectors “catch up” to a certain extent, scAAV vectors show consistently higher transgene expression and transduction efficiency months after administration (Bell et al., 2016; Natkunarajah et al., 2008; Wu et al., 2008).”
BackgroundOversized AAV Transductifon Is Mediated via a DNA-PKcs-independent, Rad51C-dependent Repair Pathway
Hirsch, M. L., Li, C., Bellon, I., Yin, C., Chavala, S., Pryadkina, M., Richard, I., & Samulski, R. J. (2013) · Molecular Therapy · doi:10.1038/mt.2013.184 · Cited by 62
Self-citationGene therapy and neurodevelopmental disorders
Gray, S. J. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.024 · Cited by 64
Moreno-Carranza, B., Gentsch, M., Stein, S., Schambach, A., Santilli, G., Rudolf, E., Ryser, M., Haria, S., Thrasher, A. J., Baum, C., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.143 · Cited by 70
5´-UTR introns enhance protein expression in the yeast Saccharomyces cerevisiae
Hoshida, H., Kondo, M., Kobayashi, T., Yarimizu, T., & Akada, R. (2016) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-7891-z · Cited by 70
“5′-UTR intron-mediated enhancement of protein expression was observed in native and artificial human promoters (Wakabayashi-Ito and Nagata 1994; Wu et al. 2008; Cooper et al. 2015), suggesting that the enhancing mechanisms might be similar in S.”
BackgroundMuscle-Specific Promoters for Gene Therapy
Skopenkova, V. V., Egorova, T. V., & Bardina, M. V. (2021) · Acta Naturae · doi:10.32607/actanaturae.11063 · Cited by 62
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
“IX was reported to increase expression 3-4-fold compared with the unaltered sequence (63).”
BackgroundWang, L., Morizono, H., Lin, J., Bell, P., Jones, D., McMenamin, D., Yu, H., Batshaw, M. L., & Wilson, J. M. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.10.020 · Cited by 52
“Such optimization has also been demonstrated with other transgenes such as human clotting factor IX that is being evaluated in a clinical trial [14, 15, 18, 36, 37].”
BackgroundHyperactive PiggyBac Transposons for Sustained and Robust Liver-targeted Gene Therapy
Matteo, M. D., Samara-Kuko, E., Ward, N. J., Waddington, S. N., McVey, J. H., Chuah, M., & VandenDriessche, T. (2014) · Molecular Therapy · doi:10.1038/mt.2014.131 · Cited by 57
Wang, M., Sun, J., Crosby, A., Woodard, K., Hirsch, M. L., Samulski, R. J., & Li, C. (2017) · Gene Therapy · doi:10.1038/gt.2016.75 · Cited by 51
“One strategy is to optimize the AAV vector cassette by utilization of a strong promoter and/or enhancer, codon-optimization of the transgenic cDNA, effective poly-adenylation sequence, and the use of a self-complementary vector genome if possible (5, 6) (7, 8).”
MethodSelf-citationNon-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
Yagi, H., Ogura, T., Mizukami, H., Urabe, M., Hamada, H., Yoshikawa, H., Ozawa, K., & Kume, A. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1543 · Cited by 56
“[34] suggested that further fine-tuning of the vector should increase the efficacy.”
BackgroundChuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 58
Xu, L., Yao, S., Ding, Y. E., Xie, M., Feng, D., Sha, P., Tan, L., Bei, F., & Yao, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05661-2 · Cited by 48
“Strikingly, introducing the Minute virus of mice (MVM) intron between promoter and transgene has been reported to increase 80-fold of transgene expression in liver cells compared to intron-null AAV [24].”
BackgroundGene therapy strategies for hemophilia: benefits versus risks
Petrus, I., Chuah, M., & VandenDriessche, T. (2010) · The Journal of Gene Medicine · doi:10.1002/jgm.1500 · Cited by 50
Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45
“IX gene expression and have gathered growing enthusiasm because of the potential for improved gene transfer and expression [11,39,40].”
BackgroundHirsch, M. L., Green, L., Porteus, M. H., & Samulski, R. J. (2010) · Gene Therapy · doi:10.1038/gt.2010.65 · Cited by 42
Self-citationSun, A., Tang, J., Terranova, P. F., Zhang, X., Thrasher, J. B., & Li, B. (2009) · International Journal of Cancer · doi:10.1002/ijc.24778 · Cited by 44
“Currently, recombinant AAV has been used extensively as gene delivery vehicles to transduce a wide range of cells in vitro and in vivo.(20,34,35) Remarkable success has also been demonstrated recently in phase I/II clinical trials in AAV-based gene therapy studies.”
MethodRecombinant Adeno-Associated Virus Utilizes Cell-Specific Infectious Entry Mechanisms
Weinberg, M. S., Nicolson, S., Bhatt, A. P., McLendon, M., Li, C., & Samulski, R. J. (2014) · Journal of Virology · doi:10.1128/jvi.01971-14 · Cited by 39
Self-citationStowaways in the cargo: Contaminating nucleic acids in rAAV preparations for gene therapy
Brimble, M. A., Winston, S. M., & Davidoff, A. M. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.07.025 · Cited by 45
Gene therapy for hemophilia – From basic science to first approvals of “one-and-done” therapies
Herzog, R. W., Kaczmarek, R., & High, K. A. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.043 · Cited by 43
Nichols, T. C., Hough, C. A., Agersø, H., Ezban, M., & Lillicrap, D. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13301 · Cited by 45
Wang, L., Wang, H., Morizono, H., Bell, P. L., Jones, D., Lin, J., McMenamin, D., Yu, H., Batshaw, M. L., & Wilson, J. M. (2011) · Gene Therapy · doi:10.1038/gt.2011.111 · Cited by 41
Luo, X., Hall, G., Li, S., Bird, A., Lavin, P., Winn, M. P., Kemper, A. R., Brown, T. T., & Koeberl, D. D. (2011) · Molecular Therapy · doi:10.1038/mt.2011.126 · Cited by 41
Corneal gene delivery: chitosan oligomer as a carrier of CpG rich, CpG free or S/MAR plasmid DNA
Klausner, E. A., Zhang, Z., Wong, S. P., Chapman, R. L., Volin, M. V., & Harbottle, R. P. (2011) · The Journal of Gene Medicine · doi:10.1002/jgm.1634 · Cited by 41
Keravala, A., Chavez, C. L., Hu, G., Woodard, L. E., Monahan, P. E., & Calos, M. P. (2011) · Gene Therapy · doi:10.1038/gt.2011.31 · Cited by 38
Self-citationJayandharan, G. R., Zhong, L., Sack, B. K., Rivers, A. E., Li, M., Li, B., Herzog, R. W., & Srivastava, A. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.100 · Cited by 38
“The liver specificity of the TTR promoter has been reported by several laboratories using a variety of genes (Scallan et al. , 2003; Liao et al. , 2006; Wu et al. , 2008).”
New approaches to gene and cell therapy for hemophilia
Ohmori, T., Mizukami, H., Ozawa, K., Sakata, Y., & Nishimura, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12926 · Cited by 30
A Muscle Hybrid Promoter as a Novel Tool for Gene Therapy
Piekarowicz, K., Bertrand, A., Azibani, F., Beuvin, M., Julien, L., Machowska, M., Bonne, G., & Rzepecki, R. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.001 · Cited by 33
AAV-Nrf2 Promotes Protection and Recovery in Animal Models of Oxidative Stress
Liang, K. J., Woodard, K., Weaver, M. A., Gaylor, J. P., Weiss, E. R., & Samulski, R. J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.016 · Cited by 34
“Evaluating promoter strength can be useful, and optimizing transgene codons has become a common strategy as well.(52) In some cases, mutations in the actual amino acid sequence of the protein can result in increased activity or availability of the protein.”
BackgroundSelf-citationHemophilia Gene Therapy: Ready for Prime Time?
VandenDriessche, T., & Chuah, M. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.116 · Cited by 32
“Nevertheless, in many cases, introns were incorporated in the constructs 9,10 to further boost expression levels that act possibly, at least in part, by facilitating extra-nuclear transport of the cognate transcripts.”
Gene therapy in an era of emerging treatment options for hemophilia B
Monahan, P. E. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12957 · Cited by 31
“Conservative nucleotide changes leading to codon optimization also yielded robust increases in factor IX expression [17] [24].”
BackgroundSelf-citationRecent Progress in Gene Therapy for Hemophilia
Chuah, M., Nair, N., & VandenDriessche, T. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.088 · Cited by 34
“…promoter/enhancer elements, codon-optimized FIX, or self-complementary, double-stranded AAV vectors (scAAV) that overcome one of the limiting steps in AAV transduction (i.e., single-stranded to double-stranded AAV conversion) (McCarty et al. , 2001, 2003; Nathwani et al. , 2006; Wu et al. , 2008).”
Ahmed, S. S., Rubin, H. L., Wang, M., Faulkner, D., Sengooba, A., Dollive, S., Avila, N., Ellsworth, J. L., Lamppu, D., Lobikin, M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.009 · Cited by 32
Yang, H., Qing, K., Keeler, G. D., Yin, L., Mietzsch, M., Ling, C., Hoffman, B. E., Agbandje‐McKenna, M., Tan, M., Wang, W., et al. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.03.009 · Cited by 32
Preclinical and clinical progress in hemophilia gene therapy
Mátrai, J., Chuah, M., & VandenDriessche, T. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833cd4bd · Cited by 36
Enhanced Factor VIII Heavy Chain for Gene Therapy of Hemophilia A
Chen, L., Lu, H., Wang, J., Sarkar, R., Yang, X., Wang, H., High, K. A., & Xiao, W. (2009) · Molecular Therapy · doi:10.1038/mt.2008.292 · Cited by 30
AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application?
van der Laan, L. J. W., Wang, Y., Tilanus, H. W., Janssen, H. L. A., & Pan, Q. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.548799 · Cited by 32
“Using scAAV, a significant reduction of the amount of vector required for sustained transgene expression in mouse liver was achieved [11].”
BackgroundAdeno-associated virus (AAV) capsid engineering in liver-directed gene therapy
Rodríguez-Márquez, E., Meumann, N., & Büning, H. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1865303 · Cited by 30
“7 vg per cell of the body, is a critical number - at least in the context of AAV2 or AAV8 vectors [63] - which increases the risk of inducing cytotoxic T lymphocytes.”
BackgroundInfluentialCabrera-Pérez, R., Vila‐Julià, F., Hirano, M., Mingozzi, F., Torres‐Torronteras, J., & Martí, R. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.217 · Cited by 31
“Also due to size limitations, the scAAV-HLP vector does not contain intron sequences, which are reported to contribute to mRNA protection and stability.(43) The self-complementary configuration favors faster expression of the transgene because scAAV vectors do not depend on cell replication machinery for their express…”
BackgroundRaj, D., Davidoff, A. M., & Nathwani, A. C. (2011) · Expert Review of Hematology · doi:10.1586/ehm.11.48 · Cited by 27
Michler, T., Große, S., Mockenhaupt, S., Röder, N., Stückler, F., Knapp, B. L., Ko, C., Heikenwälder, M. F., Protzer, U., & Grimm, D. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201506172 · Cited by 30
“The entire sequence was then cloned into an AAV vector and expressed from the liver-specific RNA polymerase II transthyretin promoter (TTR) (Wu et al, 2008).”
MethodInfluentialBell, P., Wang, L., Chen, S.-J., Yu, H., Zhu, Y., Nayal, M., He, Z., White, J., Lebel-Hagan, D., & Wilson, J. M. (2016) · Human Gene Therapy Methods · doi:10.1089/hgtb.2016.039 · Cited by 26
He, Y., Weinberg, M. S., Hirsch, M., Johnson, M. C., Tisch, R., Samulski, R. J., & Li, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.065 · Cited by 26
“Furthermore, peak levels of transgene expression are obtained significantly sooner with AAV8 as compared with AAV2 packaged vectors (Wu et al., 2008).”
BackgroundSelf-citationGene therapy for age-related macular degeneration: a promising frontier in vision preservation
Hushmandi, K., Lam, H. Y., Wong, W., Tan, W., Daryabari, S., Reiter, R. J., Farahani, N., & Kumar, A. P. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02246-4 · Cited by 26
“Although truncated versions of these transgenes have shown some success in clinical trials, alternative strategies are being explored to transport larger transgenes using AAV vectors in animal models [245–250].”
Gene Therapy for Hemophilia: Progress to Date
Chapin, J. C., & Monahan, P. E. (2017) · BioDrugs · doi:10.1007/s40259-017-0255-0 · Cited by 26
Self-citationPurdy, R., John, M., Bray, A., Clare, A. J., Copland, D. A., Chan, Y. K., Henderson, R. H., Nerinckx, F., Leroy, B. P., Yang, P., et al. (2025) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2025.101354 · Cited by 24
“Similarly, Wu et al. demonstrated that a codon-optimised vector caused 5.5-to 21.2-fold greater transgene expression, although this increase compared a single-stranded unoptimised vector to a self-complementary, optimised one (Wu et al., 2008).”
InfluentialHaemophilia gene therapy: From trailblazer to gamechanger
Evens, H., Chuah, M., & VandenDriessche, T. (2018) · Haemophilia · doi:10.1111/hae.13494 · Cited by 26
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
Marino, M., & Holt, M. G. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.870799 · Cited by 26
“This issue can be effectively overcome by creating a synthetic double-stranded genome, through mutating one of the ITRs so that it can form a short DNA hairpin—the so-called self-complementary (sc) configuration (134, 135).”
BackgroundDe, B. P., Chen, A., Salami, C. O., de Graaf, B. G. V., Rosenberg, J. B., Pagovich, O. E., Sondhi, D., Crystal, R. G., & Kaminsky, S. M. (2018) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.246 · Cited by 25
Monahan, P. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.33 · Cited by 24
Self-citationRecombinant AAV Vectors for Enhanced Expression of Authentic IgG
Fuchs, S. P., Martinez-Navío, J. M., Gao, G., & Desrosiers, R. C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158009 · Cited by 23
A Vector–Host System to Fingerprint Virus Tropism
Hillestad, M. L., Guenzel, A. J., Nath, K. A., & Barry, M. A. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.116 · Cited by 23
“The scAAV plasmid expressing codon-optimized Cre, pSC-CMV-Cre, was generated from pSC(TTR-mvm-hFIX) (Wu et al., 2008) by replacing the expression cassette with a cytomegalovirus (CMV) promoter, chimeric intron (Promega, Madison, WI), and Cre recombinase gene.”
BackgroundMethodMinimal Essential Human Factor VIII Alterations Enhance Secretion and Gene Therapy Efficiency
Cao, W., Dong, B., Horling, F., Firrman, J., Lengler, J., Klugmann, M., de la Rosa, M., Wu, W., Qizhao, W., Wei, H., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.10.013 · Cited by 21
“For the in vivo expression of BDD-FVIII (B domain replaced by the 14-amino acid SQ linker sequence) and BDD-FVIII-X5, the human wild-type coding sequence and three codon-optimized sequences (CO1, CO2, and CO3) as well as the corresponding BDD-FVIII-X5 sequences (CO1-X5, CO2-X5, and CO3-X5) were synthesized and cloned…”
MethodMontesinos, M. S., Chen, Z., & Young, S. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00713.2011 · Cited by 22
“…et al. 1998), tau 3= UTR (Aronov et al. 1999), BGH polyA (Goodwin and Rottman 1992), and MVM intron (Wu et al. 2008) cis elements can significantly increase expression in either a rAAV, rAd, or LVV context (Brun et al. 2003; Glover et al. 2002; Loeb et al. 1999; Wu et al. 2008; Xu et al. 2002).”
BackgroundMethodInfluentialAllometric-like scaling of AAV gene therapy for systemic protein delivery
Burr, A., Erickson, P., Bento, R., Shama, K. A., Roth, C. M., & Parekkadan, B. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.10.011 · Cited by 23
A small regulatory element from chromosome 19 enhances liver-specific gene expression
Li, C., Hirsch, M. L., Carter, P. J., Asokan, A., Zhou, X., Wu, Z., & Samulski, R. J. (2008) · Gene Therapy · doi:10.1038/gt.2008.134 · Cited by 20
Self-citationLengler, J., Coulibaly, S., Gruber, B., Ilk, R., Mayrhofer, J., Scheiflinger, F., Hoellriegl, W., Falkner, F. G., & Rottensteiner, H. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.013 · Cited by 19
“Published data on in vitro biopotency assays using HepG2 cells indicate that for AAV2-based vectors, FIX expression measurement requires MOIs of 2 10(5) for single-stranded and 2 10(4) for self-complementary vectors.(11,13) The obtained sensitivity for AAV vectors of serotype 8 used here is even lower and has been des…”
Kyostio-Moore, S., Berthelette, P., Piraino, S., Sookdeo, C., Nambiar, B., Jackson, R., Burnham, B. L., O’Riordan, C. R., Cheng, S. H., & Armentano, D. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.6 · Cited by 18
Giannandrea, M., Pierce, R. H., & Crispe, I. N. (2009) · Hepatology · doi:10.1002/hep.22869 · Cited by 22
Vaessen, S. F. C., Veldman, R. J., Comijn, E. M., Snapper, J., Sierts, J. A., van den Oever, K., Beattie, S. G., Twisk, J., & Kuivenhoven, J. A. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1344 · Cited by 19
“less amenable to AAV-mediated gene delivery, both when using single-stranded [38,39] or self-complementary”
Metadata
- Authors
- Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Monahan, Paul E
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2008-02
- Volume
- 16
- Issue
- 2
- Pages
- 280-289
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W1980491559
- Cited by
- 153
- References
- 50
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 8 · 2020: 11 · 2019: 5 · 2018: 6 · 2017: 10 · 2016: 10 · 2015: 5 · 2014: 11 · 2013: 6 · 2012: 8
- FWCI
- 4.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 3171 d)
- Locations
- Molecular Therapy (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Heart, Lung, and Blood Institute (P01-HL66973, P01HL066973)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- self-complementary AAV vectors, hemophilia B, factor IX, liver-directed gene delivery, cis-regulatory elements, codon usage, GC content, hepatocyte transduction
- MeSH terms
- Dependovirus, Animals, Base Composition, Hemophilia B, Codon, Factor IX, Genetic Vectors, Humans, Immunohistochemistry, Liver, Male, Mice, Inbred C57BL, Transcription, Genetic, Blotting, Southern, Genetic Therapy, Gene Expression, In Situ Hybridization, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.